NewEdge Advisors’s BioXcel Therapeutics BTAI Stock Holding History

NewEdge Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.88K	Hold	1,331	–	–	﹤0.01%	3927
2026 Q1	$1.78K	Hold	1,331	–	–	﹤0.01%	3826
2025 Q4	$2.13K	Hold	1,331	–	–	﹤0.01%	3876
2025 Q3	$3.41K	Buy	1,331 +1,300	+4,194%	+$4.1K	﹤0.01%	3643
2025 Q2	$57	Hold	31	–	–	﹤0.01%	3925
2025 Q1	$63	Hold	31	–	–	﹤0.01%	3844
2024 Q4	$187	Hold	31	–	–	﹤0.01%	3746
2024 Q3	$305	Hold	31	–	–	﹤0.01%	3654
2024 Q2	$640	Hold	31	–	–	﹤0.01%	3538
2024 Q1	$1.41K	Hold	31	–	–	﹤0.01%	3439
2023 Q4	$1.48K	Hold	31	–	–	﹤0.01%	3402
2023 Q3	$1.26K	Sell	31 -94	-75%	-$9.5K	﹤0.01%	3137
2023 Q2	$13.3K	Buy	125 +62	+98%	+$20.6K	﹤0.01%	2514
2023 Q1	$18.7K	Buy	63 +13	+26%	+$5.55K	﹤0.01%	2363
2022 Q4	$17	Buy	+50	New	+$12.1K	﹤0.01%	3622

Other funds holding BTAI

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NewEdge Advisors's BTAI Position: Q2 2026 in Review

NewEdge Advisors held its BioXcel Therapeutics (BTAI) position steady in Q2 2026 at 1,331 shares worth $1.88K. The position accounts for ﹤0.01% of the portfolio, ranked #3927.

NewEdge Advisors first reported a position in BTAI in Q4 2022 and has held it in 15 quarters since. The position peaked at $18.7K in Q1 2023. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

NewEdge Advisors held 1,331 shares of BioXcel Therapeutics worth $1.88K as of Q2 2026.
NewEdge Advisors left its BioXcel Therapeutics share count unchanged in Q2 2026.
BioXcel Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3927 holding.
NewEdge Advisors first reported a position in BioXcel Therapeutics in Q4 2022 and has held it in 15 quarters since.
NewEdge Advisors's BioXcel Therapeutics position peaked at $18.7K in Q1 2023.
47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.